CN Stock MarketDetailed Quotes

600222 Henan Taloph Pharmaceutical Stock

Watchlist
  • 4.95
  • -0.11-2.17%
Market Closed Apr 24 15:00 CST
2.84BMarket Cap65.13P/E (TTM)

About Henan Taloph Pharmaceutical Stock Company

The company was founded in 1993, and the company was solemnly listed on the Shanghai Stock Exchange in 1999, becoming the first listed company in the pharmaceutical industry in Henan Province. After more than 20 years of development, the company has successively taken indirect shares and controlled more than a dozen subsidiary (branch) companies, covering fields related to pharmaceutical manufacturing, drug research and development, capital operation, etc., and its main economic indicators rank among the top in the pharmaceutical industry in Henan Province. The company's main business is pharmaceutical manufacturing and drug research and development services, which specifically include the four business segments of pharmaceutical preparations, Chinese medicine tablets, drug research and development services, and pharmaceutical herbal medicine distribution. The company's main products include Shuanghuanglian oral liquid series, double gold combination, pediatric fever and cough relief oral liquid, pediatric antipyretic oral liquid, pediatric compound chicken neijin chewable tablets, salvia oral liquid, Shengmai drink, compound Yimu oral liquid, huxerine tablets, etc. Among them, Shuanghuanglian Oral Liquid (concentrated type), Shuanghuanglian Oral Liquid (children's type), Double Gold Combined Agent, and Pediatric Compound Chicken Neijin Chewables are the company's exclusive products. Corporate honors: “Main Enterprise in the Advanced Manufacturing Industry Chain in Zhengzhou”, the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce awarded the company the honor of “Anti-epidemic, Charity and Love”, Henan High-tech Enterprise, “National High-tech Industrialization Demonstration Project”, “Excellent Enterprise in Zhengzhou”, selected as “2022 Top 100 Chinese Pharmaceutical Industry Enterprises” by the China Traditional Chinese Medicine Association, and “2022 Top 100 Proprietary Chinese Medicine Enterprises” by the Henan Provincial People's Government, and “Key Leading Enterprise of Henan Province for Agricultural Industrialization (2024)” and “Anti-epidemic Supply and Protection Responsibility” by the China Non-Prescription Drug Association “Responsible enterprises”, “2022 Top 20 Science and Technology Innovation Enterprises” in the Zhengzhou High-tech Zone, etc.

Company Profile

Short Name-A太龙药业
Symbol-A600222
Listing DateNov 5, 1999
Issue Price6.52
Shares Offered35.00M share(s)
FoundedAug 31, 1998
Listed ExchangeSH Stock Exchange
Legal Representativehui yin
CEOjingliang li
Secretarynianyun li
Accounting FirmBeijing Xinghua Certified Public Accountants (Special General Partnership)
Securities Representativeting wu
Legal CounselHenan Qianwen Law Firm
Employees643
Phone0371-67982194
Office AddressNo. 8 Jinsuo Road, High-tech Industrial Development Zone, Zhengzhou, Henan
Zip Code450001
Registered AddressNo. 8 Jinsuo Road, High-tech Industrial Development Zone, Zhengzhou, Henan
Fax0371-67993600
Emailtaloph@taloph.com
Business License410000100015551
BusinessProduction and sale of pharmaceuticals (limited to companies and branches operating with valid licenses); production and sale of health foods; sale of pre-packaged foods; cultivation and sale of medicinal plants (according to relevant national regulations); sales of medical devices; sale of hygiene and disinfection products (excluding flammable and explosive hazardous chemicals); sales of cosmetics; consulting services, technical services; import and export business of products produced by the enterprise and related technology (except for products and technologies that are restricted by the state to operate or are prohibited from being imported and exported) (projects subject to approval by the relevant departments).

Company Executives

  • Name
  • Position
  • Salary
  • hui yin
  • Chairman,directors,Member of the Strategic Decision Committee
  • --
  • jingliang li
  • Vice Chairman,directors,general manager,Member of the Strategic Decision Committee
  • 1.17M
  • jianchao luo
  • directors,Member of the Strategic Decision Committee
  • 849.60K
  • siliang chen
  • directors,Audit Committee Member
  • --
  • jinge chen
  • directors,Member of the Remuneration and Assessment Committee
  • --
  • shiguang ma
  • directors,Nomination Committee Members
  • --
  • xiaohua yin
  • Independent directors,Member of the Remuneration and Assessment Committee,Audit Committee Member
  • 100.00K
  • liang fang
  • Independent directors,Member of the Remuneration and Assessment Committee,Nomination Committee Members
  • 100.00K
  • nianyun li
  • Board Secretary,Deputy General Manager
  • 392.90K
  • ting wu
  • Securities affairs representative
  • --
  • zhixian zhang
  • Chairman of the Supervisory Board,auditors
  • --
  • yikun wang
  • auditors
  • --
  • lizhuang zhang
  • Deputy General Manager
  • 813.20K
  • fengshan su
  • Deputy General Manager
  • 952.80K
  • hailin zhao
  • Executive Deputy General Manager,Head of finance
  • 900.70K
  • kezhen wang
  • Employee supervisors
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
%Chg